Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 601 - 625 of 15486 in total
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … types of enzyme replacement therapy for the treatment of Pompe disease include [alglucosidase alfa] and ... cipaglucosidase alfa be granted marketing authorization for the treatment of Pompe disease,[L45275] and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
Approved
Investigational
Withdrawn
Matched Iupac: … N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2H-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide …
Vericiguat is a direct stimulator of soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and hospitalizations. A key component of the NO-sGC-cGMP signaling pathway that helps to regulate the cardiovascular system, sGC enzymes are intracellular enzymes found in vascular smooth muscle cells (amongst...
Approved
Investigational
Matched Iupac: … methyl N-(4,6-diamino-2-{5-fluoro-1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}pyrimidin …
Matched Description: … soluble guanylate cyclase (sGC) used in the management of systolic heart failure to reduce mortality and ... thereby helps to prevent the myocardial and vascular dysfunction associated with decreased sGC activity ... messenger, activating a number of downstream signaling cascades that elicit a broad variety of effects, and
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Approved
Investigational
Withdrawn
Matched Description: … Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections …
Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria.
Approved
Withdrawn
Matched Description: … Long-acting plasma-bound sulfonamide used for respiratory and urinary tract infections and also for malaria …
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... artesunate, sulfalene and pyrimethamine ... Gynecological Antiinfectives and Antiseptics ... Antiparasitic Products, Insecticides and Repellents …
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
Approved
Vet approved
Matched Categories: … trichlormethiazide and potassium ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics ... trichlormethiazide and potassium-sparing agents ... Low-Ceiling Diuretics and Potassium-Sparing Agents …
Velaglucerase alfa is a gene-activated human recombinant glucocerebrosidase used for the treatment of Type 1 Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase. Additionally, Velaglucerase alfa has also been investigated for use in Type 3 Gaucher disease.
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine....
Approved
Vet approved
Matched Description: … Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals ... Therapeutic forms of trypsin is obtained from purified extracts of porcine or bovine pancreas and is ... nucleophilic attack is facilitated by the catalytic triad consisting of histidine-57, aspartate-102, and
Matched Categories: … Enzymes and Coenzymes ... Blood and Blood Forming Organs ... Preparations for Treatment of Wounds and Ulcers …
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Iupac: … 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-{[4-(pyridin-3-yl)pyrimidin-2- …
Matched Description: … A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system.
Approved
Investigational
Matched Description: … DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and
Matched Categories: … Enzymes and Coenzymes ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Intercellular Signaling Peptides and Proteins …
Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy ... Preparations for Treatment of Wounds and Ulcers …
Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved
Matched Iupac: … N''-({1,4-dioxaspiro[4.5]decan-2-yl}methyl)guanidine …
Matched Description: … Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent. …
A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797)
Approved
Withdrawn
Matched Iupac: … 3,4,6-trichloro-2-[(2,3,5-trichloro-6-hydroxyphenyl)methyl]phenol …
Matched Description: … It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders …
Matched Categories: … Phenol and Derivatives ... Antiseptics and Disinfectants …
Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.
Approved
Investigational
Matched Iupac: … 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine …
Matched Description: … Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. …
A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.
Approved
Investigational
Vet approved
Matched Categories: … Sulfonamides and trimethoprim ... sulfadimidine and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Approved
Matched Iupac: … N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-[(2E)-5-hydroxy-3-{[(oxolan-2-yl)methyl]disulfanyl}pent- …
Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase (GAA) enzyme. GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions. In Pompe disease, the...
Approved
Investigational
Matched Description: … , especially in smooth, cardiac, and skeletal muscle cells. ... muscle weakness, which leads to premature death and debilitating effects on people’s lives. ... In Pompe disease, the GAA enzyme is missing and patients are unable to properly break down glycogen, …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Valoctocogene roxaparvovec is an adeno-associated virus serotype 5 (AAV5) based gene therapy vector that expresses the B-domain deleted SQ form of human coagulation factor VIII (hFVIII-SQ). The expression of hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and increase the levels of active...
Approved
Investigational
Matched Description: … [L43282,A252807] Valoctocogene roxaparvovec was approved by EMA in September 2022 and is indicated for ... hFVIII-SQ is driven by a liver-specific promoter, which enables hepatocytes to produce factor VIII protein and ... A252797] As opposed to these therapies, valoctocogene roxaparvovec offers the advantage of continuous and
Matched Categories: … Cellular and Gene Therapy ... Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse...
Approved
Matched Description: … ], the prognosis for MCL patients remains poor and those that relapse following BTK inhibitor therapy ... Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib ... therapies have been developed that modify a patient's own T cells using viral transduction to bind to and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in...
Approved
Investigational
Matched Description: … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Skin and Mucous Membrane Agents ... Antineoplastic and Immunomodulating Agents …
Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by the deficiency of alpha-galactosidase A.[A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as agalsidase alfa and agalsidase beta, pegunigalsidase alfa uses a...
Approved
Investigational
Matched Description: … allowing it to reach target organs with a lower dose and frequency of administration. ... [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and ... While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
A potent lipoxygenase inhibitor that interferes with arachidonic acid metabolism. The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to a lesser extent. It also serves as an antioxidant in fats and oils. [PubChem]
Approved
Investigational
Matched Description: … It also serves as an antioxidant in fats and oils. [PubChem] ... The compound also inhibits formyltetrahydrofolate synthetase, carboxylesterase, and cyclooxygenase to …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Trilostane is an inhibitor of 3 beta-hydroxysteroid dehydrogenase used in the treatment of Cushing's syndrome. It was withdrawn from the United States market in April 1994.
Approved
Investigational
Vet approved
Withdrawn
Matched Categories: … Sex Hormones and Insulins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Displaying drugs 601 - 625 of 15486 in total